Abstract
Background: Patients with chronic kidney disease (CKD) are at increased risk of muscle wasting. Screening tools for sarcopenia, including the Sarc‐F questionnaire are now advocated for clinical practice. We wished to compare using the Sarc‐F tool with standard measurements of hand grip (HGS) strength and appendicular muscle mass index (APMI).Methods: We retrospectively reviewed Sarc‐F questionnaires completed by patients with CKD, along with contemporaneous measurements of HGS and bioimpedance measured APMI.Results: 146 patients; 94 male (64.4%), mean age 70.5 ± 15 years, body mass index 28.7 ± 6.3 kg/m2 were screened, and 46 screened positive for sarcopenia, with a lower median HGS (19.3 (14.2–24.7) vs 25.6 (19.7–32) kg) and greater body fat (38.3 ± 11.5 vs 30.6 ± 11.5%), both p < 0.001,, with more non‐white ethnicity (63 vs 44%), p < 0.05, but there were no other differences. Step‐wise adding HGS, and then APMI cut offs, the prevalence of sarcopenia fell from 31.5% to 20.7–24.7% and 2.8–4.8% respectively, with 45.5–62.8% having reduced HGS strength and 11.0–28.1% reduced APMI, depending on which guidelines were applied. Using the most recent European, and ethnicity adjusted cut‐off values then there were no statistical differences in the prevalence of sarcopenia with or without the Sarc‐F screening tool.Conclusions: By starting with the Sarc‐F screening tool, a number of our patients with CKD would then have been excluded from subsequent investigation for sarcopenia. However, overall screening with the Sarc‐F tool did not lead to a significant difference in the prevalence of sarcopenia, when using current and ethnicity adjusted guidelines, compared to combining HGS and APMI alone.

This publication has 9 references indexed in Scilit: